Compare iShares Core MSCI Emerging Markets ETF (IEMG) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Core MSCI Emerging Markets ETF vs Zimmer Biomet Holdings Inc — how do they compare? iShares Core MSCI Emerging Markets ETF trades at $81.4 (market cap $162.00B), while Zimmer Biomet Holdings Inc trades at $89.14 (market cap $16.95B). The key difference: iShares Core MSCI Emerging Markets ETF is far larger — about 9.6× Zimmer Biomet Holdings Inc's market cap, and Zimmer Biomet Holdings Inc pays a 1.08% dividend while iShares Core MSCI Emerging Markets ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares Core MSCI Emerging Markets ETF for 57 Days and Zimmer Biomet Holdings Inc for 89 Days on average.
| IEMG | ZBH | |
|---|---|---|
Market Cap | $162.00B | $16.95B |
Volume | 13,446,151 | 2,505,240 |
Sector | Broad Market / Factor | Health |
52-Week High | $86.00 | $103.98 |
52-Week Low | $64.22 | $79.58 |
Typical Hold Time | 57 Days | 89 Days |
Enterprise Value | — | $24.02B |
Dividend Yield | — | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IEMG is trading at $80.5, down 1.88% over the past 24 hours amid a bearish technical signal. The ETF's technical indicators show selling pressure with moving averages signaling bearish momentum, though oscillators remain neutral. Recent news highlights IEMG's strong performance against emerging market peers, with the fund delivering 35% returns over the past year according to Fool - Investing News on 2026-07-06, though it faces higher volatility than broader international alternatives.
The outlook for IEMG remains mixed with technical weakness offset by strong recent performance in emerging markets. Key risks include concentration in technology sectors (39% weighting) and higher volatility compared to developed market ETFs. Analyst comparisons favor IEMG for emerging market exposure but note cost disadvantages versus competitors like SCHE with its 0.03% expense ratio versus IEMG's 0.09%.
Zimmer Biomet (ZBH) trades at $88.91, up 0.47% today, with a bearish technical signal from moving averages. The company reported Q2 2026 EPS of $2.07, beating estimates, and raised its 2026 outlook. Revenue growth remains steady, with 2025 revenue at $8.23B, though net income margin declined to 8.56%. The stock is supported by a quarterly dividend of $0.24 and a consensus price target of $103.11, suggesting potential upside.
The outlook is mixed: strong fundamentals and analyst optimism contrast with technical weakness. Investment opportunities include consistent earnings beats and dividend income, but risks involve rising debt levels and competitive pressures in the medical technology sector. The stock's current valuation at a P/E of 21.57 appears reasonable if growth continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares Core MSCI Emerging Markets ETF
IEMG tracks the MSCI Emerging Markets Investable Market Index, providing broad exposure to large, mid, and small-cap stocks across over 20 emerging market countries. It is designed as a low-cost core holding for investors seeking diversified growth from economies outside of developed markets.
Read more on IEMG →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
